Loading...
XNAS
PMCB
Market cap6mUSD
Jul 22, Last price  
0.99USD
1D
-0.57%
1Q
-16.86%
Jan 2017
-99.56%
IPO
-99.21%
Name

PharmaCyte Biotech Inc

Chart & Performance

D1W1MN
P/E
20.35
P/S
EPS
0.05
Div Yield, %
Shrs. gr., 5y
67.19%
Rev. gr., 5y
%
Revenues
0k
86,374537,0381,169,6581,189,954653,134262,932125,99766,55812,16000000000000
Net income
334k
P
-4,276,894-9,385,323-3,614,279-3,791,966-6,041,624-5,991,925-1,397,716-1,899,312-1,598,102-27,254,020-10,854,509-6,063,784-4,443,685-6,828,841-4,067,228-3,827,341-3,554,282-4,085,799-4,315,993333,763
CFO
-2m
L-43.29%
-2,797,687-1,072,188-351,596-1,191,073-1,185,372-974,057-225,232-259,289-390,426-1,562,562-4,560,169-4,346,406-3,339,462-5,079,395-2,877,912-2,338,373-3,330,889-4,117,319-3,793,731-2,151,457
Earnings
Aug 11, 2025

Profile

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
IPO date
Sep 11, 2003
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑042016‑04
Income
Revenues
Cost of revenue
6,520
6,455
Unusual Expense (Income)
NOPBT
(6,520)
(6,455)
NOPBT Margin
Operating Taxes
(1,937)
Tax Rate
NOPAT
(6,520)
(4,518)
Net income
334
-107.73%
(4,316)
5.63%
Dividends
Dividend yield
Proceeds from repurchase of equity
(44,358)
(13,561)
BB yield
218.39%
23.83%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
12,968
Net debt
(50,180)
(69,612)
Cash flow
Cash from operating activities
(2,151)
(3,794)
CAPEX
Cash from investing activities
(5,000)
Cash from financing activities
(10,708)
(13,560)
FCF
(6,520)
(4,518)
Balance
Cash
50,180
68,040
Long term investments
1,572
Excess cash
50,180
69,612
Stockholders' equity
(103,779)
(115,980)
Invested Capital
156,262
188,670
ROIC
ROCE
EV
Common stock shares outstanding
9,581
19,489
Price
2.12
-27.40%
2.92
25.32%
Market cap
20,312
-64.31%
56,908
57.36%
EV
(18,001)
(12,704)
EBITDA
(6,520)
(6,455)
EV/EBITDA
2.76
1.97
Interest
Interest/NOPBT